TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

David R Spigel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.